Overview
Infectious embryofetopathy refers to a group of congenital conditions caused by maternal infections transmitted to the developing embryo or fetus during pregnancy. These infections can occur at various stages of gestation and may lead to a wide spectrum of structural malformations, organ damage, and functional impairments depending on the timing of infection and the causative pathogen. The term encompasses damage caused by well-known teratogenic infectious agents including, but not limited to, rubella virus, cytomegalovirus (CMV), Toxoplasma gondii, herpes simplex virus, varicella-zoster virus, Zika virus, and Treponema pallidum (syphilis) — historically grouped under the acronym TORCH infections. The body systems most commonly affected include the central nervous system (microcephaly, intracranial calcifications, intellectual disability, sensorineural hearing loss), the eyes (chorioretinitis, cataracts, microphthalmos), the cardiovascular system (congenital heart defects), and the liver and spleen (hepatosplenomegaly, jaundice). Growth restriction, thrombocytopenia with petechiae, and skeletal abnormalities may also be present. The severity of the embryofetopathy depends on the gestational age at the time of infection, with first-trimester infections generally causing the most severe structural malformations. Treatment is largely supportive and depends on the specific organ systems involved. Some infections, such as congenital toxoplasmosis and congenital syphilis, can be treated with antimicrobial therapy during pregnancy or in the neonatal period to reduce disease severity. Antiviral agents (e.g., ganciclovir for symptomatic congenital CMV) may be used in select cases. Prevention through maternal vaccination (e.g., rubella, varicella), screening programs, and hygiene measures remains the most effective strategy. Long-term multidisciplinary follow-up involving neurology, ophthalmology, audiology, and developmental specialists is typically required.
Neonatal
Begins at or shortly after birth (first 4 weeks)
Treatments
No FDA-approved treatments are currently listed for Infectious embryofetopathy.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Infectious embryofetopathy at this time.
New trials open frequently. Follow this disease to get notified.
Specialists
View all specialists →No specialists are currently listed for Infectious embryofetopathy.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Infectious embryofetopathy.
Community
No community posts yet. Be the first to share your experience with Infectious embryofetopathy.
Start the conversation →Latest news about Infectious embryofetopathy
No recent news articles for Infectious embryofetopathy.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Infectious embryofetopathy
What is Infectious embryofetopathy?
Infectious embryofetopathy refers to a group of congenital conditions caused by maternal infections transmitted to the developing embryo or fetus during pregnancy. These infections can occur at various stages of gestation and may lead to a wide spectrum of structural malformations, organ damage, and functional impairments depending on the timing of infection and the causative pathogen. The term encompasses damage caused by well-known teratogenic infectious agents including, but not limited to, rubella virus, cytomegalovirus (CMV), Toxoplasma gondii, herpes simplex virus, varicella-zoster virus
At what age does Infectious embryofetopathy typically begin?
Typical onset of Infectious embryofetopathy is neonatal. Age of onset can vary across affected individuals.